UCB nabs bigger market for seizure med Vimpat; AZ's Brilinta safe for ambulance use, but not more beneficial;

@FiercePharma: ICYMI: Are specialty pharma CEOs worth their salt? Story | Follow @FiercePharma

@EricPFierce: Pablo Manuel Fernandez is on the the FDA Most Wanted list. He sold $12M worth of counterfeit Viagra. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Are specialty pharma CEOs worth their salt? More | Follow @CarlyHFierce

> UCB won broader approval for its epilepsy drug Vimpat as monotherapy for patients with partial-onset seizures; it's already approved as an add-on in these patients, but the new indication covers a much larger market. Report

> AstraZeneca's ($AZN) bloodthinner Brilinta is safe to use in heart attack victims during transport to the hospital, but this early use didn't offer any added benefit to later use. Report

> Johnson & Johnson ($JNJ) and Bayer's anticoagulant drug Xarelto is a solid alternative to warfarin in atrial fibrillation patients undergoing cardioversion to return their heart rhythm to normal, a study found. Report

> Denmark's Lundbeck rolled out its neurological drug Northera in the U.S. after approval by the FDA. Report

> New concerns about a Servier heart rate drug arose in a new study, which found that patients with a severe form of angina did worse when using the med. Report

> Hospital admissions for skin cancer soared by 41% in England over the past 5 years, a study found, with a 30% increase in cases of the most deadly form, melanoma. Report

Medical Device News

@FierceMedDev: ICYMI: looks to sell off Cordis for as much as $2B. Article | Follow @FierceMedDev

@VarunSaxena2: Attorney: Latest UDI guidance unhelpful, many questions left unanswered. Story | Follow @VarunSaxena2

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. FierceDrugDelivery story | Follow @MichaelGFierce

> Boston Scientific faces stinging setback for vagus nerve stimulation device in mid-stage trial. Story

> Dime-sized device can separate healthy and cancerous cells. Article

> Can the nose bone be connected to the knee bone? More

Biotech News

@FierceBiotech: Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data. Article | Follow @JohnCFierce

@EmilyMFierce: On-off switch found for natural antibiotics maker. Story | Follow @EmilyMFierce

> Acadia surges after nabbing 'breakthrough' title for late-stage Parkinson's drug. News

> Novo Nordisk abandons anti-inflammatory R&D work, spotlights diabetes, obesity. Article

> Cabozantinib flops against prostate cancer, forcing big jobs cuts at Exelixis. Report

CRO News

> Synexus snags another South African site and widens its footprint. Report

> Cenix lands an early-phase deal with BASF's Metanomics. News

> CRO Onyx signs up to help CRUK handle cancer R&D. More

> PRA sets sights on a new HQ. Story

> Catalent lends its weight to an armed-antibody cancer candidate. Article

Biotech IT News

> J&J, Sanofi apply IBM's Watson to R&D. News

> Takeda strikes deal with C4X to access 3D drug structure tech. Article

> Apple tightens health data privacy rules ahead of HealthKit launch. More

> Hackers target pharma's 'golden nuggets' to steal a lead in R&D. Story

> Amazon's meeting with FDA starts the rumor mill turning. Item

Animal Health News

> Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program. News

> Survey: Midwest corridor is a global magnet for animal health companies. Report

> Could a pair of offerings be the first signs of animal health IPO momentum? Article

> Mars Petcare issues four-state recall for 22 bags of Pedigree dog food. Story

> New Zealand's Simcro to set up North American HQ in Kansas. More

Biotech Research News

> Japanese institute to cut back stem cell research in wake of scandal. More

> Japanese institute to cut back stem cell research in wake of scandal. Report

> Gene therapy prevents botulism in mice. Article

> ZMapp antibody therapy prevents Ebola infection in monkeys. Item

> Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. Story

Pharma Manufacturing News

> Indian drugmakers giving up 'advantage' to move to higher-margin drugs. More

> Adcock shareholder on defense for opposing buyout by CFR. News

> Could a pair of offerings be the first signs of animal health IPO momentum? More

> Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant. Story

> Sources: West Pharmaceutical looks at $130M investment in Ireland. Article

And Finally... In lowering blood pressure and controlling blood sugar, there is such a thing as too much treatment. Report (sub. req.)

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.